ADPKD: Understanding immunosuppression mechanisms and discovering treatment
ADPKD: Understanding immunosuppression mechanisms and discovering treatment
批准号:
10633246
负责人:
Xiaogang Li
金额:
$46.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2025-06-30
关键词:
AffectAnimal ModelAntibodiesAreaAutosomal Dominant Polycystic KidneyBindingCell CommunicationCell physiologyCellsClinicalCollagenCommunicationCystCystic kidneyDataDendritic CellsDevelopmentDiseaseDisease ProgressionEpithelial Cell ProliferationEpithelial CellsFibroblastsGelGeneticGrowthHumanImmuneImmune EvasionImmune responseImmune systemImmunologic SurveillanceImmunosuppressionImmunosuppressive AgentsImmunotherapyInflammationInvestigationKidneyKnock-outKnockout MiceLigandsMacrophageMediatingMigration Inhibitory FactorMusMutant Strains MicePatientsPlayPopulationPublicationsReportingRoleSignal TransductionStimulusStructureSurfaceT-Cell ActivationT-Cell ReceptorT-LymphocyteTNF geneTestingTimeTissuesTumor EscapeTumor-infiltrating immune cellsUp-RegulationUrinecancer cellcytokineexosomehuman modelhumanized antibodyimprovedin vivoinhibitorinterstitiallymphocyte proliferationmouse modelmutantmutant mouse modelneoplastic cellnovel therapeutic interventionpre-clinicalprogrammed cell death ligand 1programmed cell death protein 1recruitrenal epitheliumtumortumor microenvironmenttumor-immune system interactionsurinary
中文摘要
总结
英文摘要
Summary
The immune system plays an important role in protecting us from disease. Interstitial inflammation has
been consistently reported in human and animal models of ADPKD, and it may become worse during cyst
expansion which results in more damages in renal parenchyma. In addition to the increase of macrophages
in the interstitium and pericystic areas, T lymphocytes are also increased in cystic kidneys. However,
whether and how PKD mutant cystic renal epithelial cells escapes immune attacks in cystic
microenvironment during cyst initiation and expansion remains elusive. In this study, we investigate the roles
of programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1), a PD-1 ligand, in
ADPKD. We found that, 1) PD-1 was upregulated on T cells in Pkd1 mutant kidneys; 2) PD-L1 was
upregulated in Pkd1 mutant renal epithelial cells and tissues, and was increased in cystic cell derived
exosomes; 3) knockout of Pd-l1 delayed cyst growth and increased the survival of Pkd1 knockout mice; 4)
targeting PD1 and PD-L1 with antibodies delayed cyst growth in Pkd1 knockout kidneys; 5) treatment with
exosomes isolated from cystic renal epithelial cells and urine of ADPKD patients increased Pkd1 wild type
renal epithelial cell proliferation, and induced the activation of PKD associated signaling in these cells; 6)
treatment with cystic renal epithelial cell derived exosomes promoted cyst growth in Pkd1 mutant kidneys; 7)
renal epithelial cells (NRK-52E cells) treated with ADPKD urinary exosomes also developed cysts-like
structures in collagen gels; and 8) inhibition of exosome secretion with GW4869 delays cyst growth in Pkd1
knockout kidneys. Our central hypothesis is that upregulation of PD-L1 on cystic renal epithelial cells and
PD-1 on T cells results in immune evasion of cystic cells via inhibition of T cell function, and exosomes
secreted by cystic renal epithelial cell regulate immunosuppression via adjacent T cells and the function of
other neighboring cells, including renal epithelial cells and fibroblasts, contributing to cyst growth. We test
this hypothesis with three specific aims. This study will determine for the first time whether PD-1 and PD-L1
are immune-suppressors in cystic kidneys, which helps cystic epithelial cells to escape immune attack in
ADPKD, and whether exosomes secreted by cystic epithelial cells contribute to immune suppression and
other cellular communication. In addition, we will determine whether PD1 and PD-L1 are effective targets to
slow disease progression in preclinical setting. Accomplishing this study will lead to a better understanding
of the mechanism of immune surveillance in renal cyst formation and the roles of cystic cell exosomes in
regulating immunosuppression and other cell-to-cell communication, which will provide novel therapeutic
strategy for ADPKD treatment.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3390/ijms24087647
发表时间:
2023-04-21
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[Samarpita S, Li X]
通讯作者:
Li X
Lysyl oxidase promotes renal fibrosis via accelerating collagen cross-link driving by β-arrestin/ERK/STAT3 pathway.
赖氨酰氧化酶通过 β-arrestin/ ERK/STAT3 途径加速胶原蛋白交叉链接,促进肾纤维化
DOI:
10.1096/fj.202200573r
发表时间:
2022-08
期刊:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.3390/metabo12010058
发表时间:
2022-01-10
期刊:
Metabolites
影响因子:
4.1
作者:
[Zhang X, Li X]
通讯作者:
Li X
DOI:
10.1038/s41419-023-06323-9
发表时间:
2023-12-05
期刊:
CELL DEATH & DISEASE
影响因子:
9
作者:
[Zhang, Lu, Zhang, Hongbing, Agborbesong, Ewud, Zhou, Julie Xia, Li, Xiaogang]
通讯作者:
Li, Xiaogang
DOI:
10.3389/fmolb.2022.922428
发表时间:
2022
期刊:
Frontiers in molecular biosciences
影响因子:
5
作者:
[]
通讯作者:
共 15 条
ADPKD: Understanding immunosuppression mechanisms and discovering treatment
-
批准号:10274630
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2021
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: Understanding immunosuppression mechanisms and discovering treatment
-
批准号:10468127
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2021
-
负责人:Xiaogang Li
-
依托单位:
The crosstalk of DNA and lysine methyltransferases in ADPKD.
-
批准号:10264040
-
项目类别:
-
资助金额:$48.43万
-
财政年份:2020
-
负责人:Xiaogang Li
-
依托单位:
The crosstalk of DNA and lysine methyltransferases in ADPKD.
-
批准号:10680391
-
项目类别:
-
资助金额:$48.43万
-
财政年份:2020
-
负责人:Xiaogang Li
-
依托单位:
The crosstalk of DNA and lysine methyltransferases in ADPKD.
-
批准号:10092241
-
项目类别:
-
资助金额:$48.43万
-
财政年份:2020
-
负责人:Xiaogang Li
-
依托单位:
The crosstalk of DNA and lysine methyltransferases in ADPKD.
-
批准号:10449249
-
项目类别:
-
资助金额:$48.43万
-
财政年份:2020
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: Understanding mechanisms, Discovering treatments.
-
批准号:8116536
-
项目类别:
-
资助金额:$32.3万
-
财政年份:2010
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: Understanding mechanisms, Discovering treatments.
-
批准号:8712471
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2010
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: Understanding mechanisms, Discovering treatments.
-
批准号:7889056
-
项目类别:
-
资助金额:$32.63万
-
财政年份:2010
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: Understanding mechanisms, Discovering treatments.
-
批准号:8537910
-
项目类别:
-
资助金额:$31.38万
-
财政年份:2010
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: Understanding mechanisms, Discovering treatments.
-
批准号:8598998
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2010
-
负责人:Xiaogang Li
-
依托单位:
ADPKD: understanding mechanisms and discovering treatments
-
批准号:9175660
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2010
-
负责人:Xiaogang Li
-
依托单位:
Biomedical Research Core 2: Epigenetics Core
-
批准号:9754122
-
项目类别:
-
资助金额:$17.38万
-
财政年份:--
-
负责人:Xiaogang Li
-
依托单位:
Biomedical Research Core 2: Epigenetics Core
-
批准号:8973947
-
项目类别:
-
资助金额:$17.38万
-
财政年份:--
-
负责人:Xiaogang Li
-
依托单位:
Biomedical Research Core 2: Epigenetics Core
-
批准号:9323431
-
项目类别:
-
资助金额:$17.38万
-
财政年份:--
-
负责人:Xiaogang Li
-
依托单位:
海外基金